ReviewCurrent cardiology reports2015
Statin intolerance: diagnosis and remedies.
Review in Current cardiology reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Effects of probiotics combined with statins on blood lipids, TMAO, and inflammatory and oxidative stress markers in patients with atherosclerosis: a systematic review and meta-analysis.Frontiers in cardiovascular medicine · 2026Pooled it
- LDL-Cholesterol-Lowering Therapy.Handbook of experimental pharmacology · 2022Article
- Real-world safety of PCSK9 inhibitors: A pharmacovigilance study based on spontaneous reports in FAERS.Frontiers in pharmacology · 2022Article
- Perinatal Outcomes After Statin Exposure During Pregnancy.JAMA network open · 2021Article
- Effect of a pharmacy comprehensive chronic diseases care plan on use of lipid-lowering drugs among patients with hypertension.Journal of managed care & specialty pharmacy · 2021Article
- Transatlantic Lipid Guideline Divergence: Same Data But Different Interpretations.Journal of the American Heart Association · 2020Review
- Statin Use Associates With Risk of Type 2 Diabetes via Epigenetic Patterns atFrontiers in genetics · 2020Article
- In vivo genome and base editing of a human PCSK9 knock-in hypercholesterolemic mouse model.BMC biology · 2019Article
- Implementing genome-driven personalized cardiology in clinical practice.Journal of molecular and cellular cardiology · 2018Review
- Nutraceuticals in the management of patients with statin-associated muscle symptoms, with a note on real-world experience.Clinical cardiology · 2018Review
- Practical Considerations for the Use of Subcutaneous Treatment in the Management of Dyslipidaemia.Advances in therapy · 2017 · on this mapReview
- Efficacy of alirocumab according to background statin type and dose: pooled analysis of 8 ODYSSEY Phase 3 clinical trials.Scientific reports · 2017Article
- Four Statin Benefit Groups Defined by The 2013 ACC/AHA New Cholesterol Guideline are Characterized by Increased Plasma Level of Electronegative Low-Density Lipoprotein.Acta Cardiologica Sinica · 2016Article
- Review
- Functional food red yeast rice (RYR) for metabolic syndrome amelioration: a review on pros and cons.World journal of microbiology & biotechnology · 2016Review
- Innovative Target Therapies Are Able to Block the Inflammation Associated with Dysfunction of the Cholesterol Biosynthesis Pathway.International journal of molecular sciences · 2015Review
- Statin Intolerance: the Clinician's Perspective.Current atherosclerosis reports · 2015Review
- Oestrogen-modulated gene expression in the human endometrium.Cellular and molecular life sciences : CMLS · 2005Article
- Current and emerging treatments for hypercholesterolemia: A focus on statins and proprotein convertase subtilisin/kexin Type 9 inhibitors for perioperative clinicians.Journal of anaesthesiology, clinical pharmacologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the efficacy of statins in reducing cardiovascular events in both primary and secondary prevention, the adherence to statin therapy is not optimal, mainly due to the occurrence of muscular adverse effects. Several risk factors may concur to the development of statin-induced myotoxicity, including patient-related factors (age, sex, and race), statin properties (dose, lipophilicity, and type of metabolism), and the concomitant administration of other drugs. Thus, the management of patients intolerant to statins, particularly those at high or very high cardiovascular risk, involves alternative therapies, including the switch to another statin or the use of intermittent dosage statin regimens, as well as nonstatin lipid lowering drugs (ezetimibe and fibrates) or new hypolipidemic drugs such as PCSK9 monoclonal antibodies, the antisense oligonucleotide against the coding region of human apolipoprotein B mRNA (mipomersen), and microsomal triglyceride transfer protein inhibitor lomitapide. Ongoing clinical trials will reveal whether the lipid-lowering effects of alternative therapies to statins can also translate into a cardiovascular benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.